Stay updated on Pembrolizumab in SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in SCLC Clinical Trial page.

Latest updates to the Pembrolizumab in SCLC Clinical Trial page
- Check5 days agoChange DetectedThe record presents details of a terminated Phase 2 study of pembrolizumab with chemotherapy, with or without radiation, for extensive-stage small cell lung cancer. It includes the study design, eligibility criteria, interventions, outcomes, and a link to the study protocol.SummaryDifference59%

- Check12 days agoChange DetectedThe ClinicalTrials.gov footer now shows revision v3.8.0 instead of v3.7.2. The study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA site-wide notice says NIH websites are transitioning terminology from “Artificial Intelligence” to “Super Intelligence.” The site revision label changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check40 days agoChange DetectedThe ClinicalTrials.gov page remains blocked by a 403 error, with the displayed site revision updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check54 days agoChange DetectedThe page content has shifted from detailed study information to an access-restricted 403 error, with a standard site header/footer visible and an explicit 403 message, effectively rendering the study information unavailable.SummaryDifference20%

- Check61 days agoChange DetectedThe page’s internal version was updated to v3.7.0, indicating a maintenance update to the site’s infrastructure. This change does not modify the study text or visible information on the page.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in SCLC Clinical Trial page.